Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 55Specimen Handling 47Magnetic Resonance Spectroscopy 39Cisplatin 34olaparib 28Gemcitabine 26liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12Letrozole 12lenvatinib 11Surveys and Questionnaires 11atezolizumab 10Drug Therapy 10Brachytherapy 10durvalumab 9Radiotherapy 9Fulvestrant 9Docetaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
VMBP protocol × Gynecologic × 90 days × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡